Aditxt Inc. (NASDAQ: ADTX) Announces Goal of First-in-Human Trials for Drug Candidate ADI(TM)-100 with a Focus on Psoriasis
- Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials
- The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3%
- The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed to evaluate the ability of ADI(TM) to restore immune tolerance
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies are being developed to retrain the immune system to induce tolerance, to address, among other things, the rejection of transplanted organs, autoimmune diseases and allergies. The company’s first commercial product, AditxtScore(TM), is designed to provide a personalized immune system profile.
In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune(TM) initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s(TM) nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance in an antigen-specific way without impairing the immune response to fight infections and cancer.
According to Amro Albanna, co-founder, chairman, and CEO of Aditxt, the company’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation.
“We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s(TM) initiation of ADI(TM)-100 manufacturing is measurable progress of Adimune(TM) toward our 2023 strategic goals,” Albanna added (https://nnw.fm/93dxg ). The company is focused on the concept of “moving from infection status to protection status.”
Psoriasis is a persistent skin disorder characterized mainly by skin irritation and scaly rashes where skin cells multiply up to 10 times faster than normal. It is classified as a non-contagious autoimmune disease and is considered to be a long-term disorder. The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3%. The market is expected to grow due to the rising awareness and incidence of psoriasis and skin disorders associated with it globally (https://nnw.fm/3hRWi ).
The safety profile for the drug candidate was earlier established in preclinical toxicology studies for ADI(TM)-100. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the Therapeutics Business Unit at the multinational pharmaceutical company Schering AG, is leading Adimune’s(TM) ADI(TM) immune modulation technology development toward clinical trials.
Dr. Kapp spoke about the psoriasis trial, saying that Adimune’s(TM) approach to treating autoimmune diseases may have a game-changing impact in a worldwide market estimated at 125 million psoriasis patients and more than 1.2 million Type 1 diabetes patients under the age of 20.
“The ADI(TM) technology is very different from immunosuppressant drugs in that it restores immune tolerance. Our proof-of-concept trials are designed to demonstrate just that,” he explained.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Dr. Joachim-Friedrich Kapp is leading Aditxt’s ADI(TM) immune modulation technology development toward clinical trials
- The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3%
- The primary goal of the first-in-human clinical trial is to demonstrate the safety of Aditxt’s ADI(TM) technology; in addition, the trial has been designed to evaluate the ability of ADI(TM) to restore immune tolerance
Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies are being developed to retrain the immune system to induce tolerance, to address, among other things, the rejection of transplanted organs, autoimmune diseases and allergies. The company’s first commercial product, AditxtScore(TM), is designed to provide a personalized immune system profile.
In late October 2022, Aditxt announced the creation of its Adimune(TM) program. At the same time, Aditxt announced that Adimune(TM) initiated the GMP manufacturing of drug candidate ADI(TM)-100 for purposes of initiating human trials. The trial will be performed in autoimmune diseases, with psoriasis as the first indication to be studied. Adimune’s(TM) nucleic acid-based technology, ADI(TM), has shown in preclinical studies the ability to restore/induce immune tolerance in an antigen-specific way without impairing the immune response to fight infections and cancer.
According to Amro Albanna, co-founder, chairman, and CEO of Aditxt, the company’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation.
“We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s(TM) initiation of ADI(TM)-100 manufacturing is measurable progress of Adimune(TM) toward our 2023 strategic goals,” Albanna added (https://nnw.fm/93dxg ). The company is focused on the concept of “moving from infection status to protection status.”
Psoriasis is a persistent skin disorder characterized mainly by skin irritation and scaly rashes where skin cells multiply up to 10 times faster than normal. It is classified as a non-contagious autoimmune disease and is considered to be a long-term disorder. The global psoriasis therapeutics market was valued at $22.9 billion in 2021 and is projected to reach $55.8 billion by 2031, growing at a CAGR of 9.3%. The market is expected to grow due to the rising awareness and incidence of psoriasis and skin disorders associated with it globally (https://nnw.fm/3hRWi ).
The safety profile for the drug candidate was earlier established in preclinical toxicology studies for ADI(TM)-100. Dr. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the Therapeutics Business Unit at the multinational pharmaceutical company Schering AG, is leading Adimune’s(TM) ADI(TM) immune modulation technology development toward clinical trials.
Dr. Kapp spoke about the psoriasis trial, saying that Adimune’s(TM) approach to treating autoimmune diseases may have a game-changing impact in a worldwide market estimated at 125 million psoriasis patients and more than 1.2 million Type 1 diabetes patients under the age of 20.
“The ADI(TM) technology is very different from immunosuppressant drugs in that it restores immune tolerance. Our proof-of-concept trials are designed to demonstrate just that,” he explained.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
